Last reviewed · How we verify
Toripalimab mimetic (placebo)
Toripalimab mimetic is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.
Toripalimab mimetic is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Nasopharyngeal carcinoma.
At a glance
| Generic name | Toripalimab mimetic (placebo) |
|---|---|
| Also known as | Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, Toripalimab mimetic allows T cells to recognize and attack cancer cells more effectively. This mechanism is particularly useful in treating various types of cancer, including non-small cell lung cancer and nasopharyngeal carcinoma.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Nasopharyngeal carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pyrexia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: